JRK Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human JRK gene in the HeLa host line. Generated by CRISPR/Cas9-mediated gene disruption, this product provides a mixed population of edited cells that reflects a range of loss-of-function alleles, circumventing the need for single-cell cloning. The polyclonal format enables the interrogation of heterogeneous knockout phenotypes and is ideal for pathway analysis, functional genomics, and initial screening studies where clonal variability is experimentally informative.
The host HeLa cell line is an HPV18-positive cervical adenocarcinoma model with adherent epithelial morphology. Originating from a cancer biopsy, HeLa cells are immortalized and widely adopted in biomedical research due to their robust proliferation, well-documented genomic landscape, and compatibility with a broad array of molecular and cellular techniques. Their transformed nature makes them particularly relevant for studying oncogenic signaling, cell cycle dysregulation, and transcriptional control mechanisms.
JRK encodes a transcriptional regulator distinguished by a plant homeodomain (PHD) finger that directly binds modified histone H3, linking epigenetic marks to gene expression. It operates upstream of critical cell cycle regulatory genes, including CCND1 (cyclin D1) and CDKN1A (p21), and engages with chromatin remodeling complexes, as well as cell cycle kinases that modulate its activity. In this network, JRK intersects with CDK4, the retinoblastoma protein RB1, and the E2F1 transcription factor, integrating proliferation signals with chromatin state to control target gene output. Additionally, it interacts with other PHD finger proteins and transcriptional co-regulators, forming part of a broader epigenetic regulatory machinery.
Disruption of JRK in HeLa cells is anticipated to disturb cell cycle progression and transcriptional programs linked to proliferation and genomic stability. Given the oncogenic potential of the HeLa background, this model allows dissection of how epigenetic readers such as JRK influence division rates, checkpoint control, and global transcription in a cancer-relevant context. Furthermore, the polyclonal nature captures a spectrum of editing events, supporting dose-response studies and revealing dominant versus recessive effects that may be masked in pure clonal lines.
Applications for this knockout model span cell cycle research, transcriptional regulation studies, functional genomics, and drug screening for epilepsy and neurodevelopmental disorders, where JRK has been implicated. Compatible assays include Western blotting for JRK protein levels, RT-qPCR for transcript quantification, cell cycle flow cytometry, proliferation assays (e.g., EdU/MTS), RNA-seq transcriptomics, and ChIP-qPCR to examine histone modification changes. The product also serves as a robust control in CRISPR-based genetic screens. For further details or to discuss custom projects, please contact Ascent Research.
